User login
Key clinical point: Adherence to the American Institute for Cancer Research and American Cancer Society’s lifestyle recommendations reduced the risk for disease recurrence and improved mortality in patients with high-risk breast cancer (BC).
Major finding: Patients in the highest vs lowest tertile of lifestyle index scores (LIS) experienced a 37% reduction in recurrence (hazard ratio [HR] 0.63; 95% CI 0.48-0.82) and those in the middle (HR 0.70; P = .03) and highest (HR 0.42; P < .001) vs lowest tertile of LIS had significant reductions in mortality.
Study details: Findings are from the prospective, observational, DELCaP (The Diet, Exercise, Lifestyles, and Cancer Prognosis) study including 1340 chemotherapy-naive women with high-risk stage I to III BC, of which the majority (65.3%) of women had hormone receptor-positive BC.
Disclosures: This study was supported by the US National Cancer Institute and The Breast Cancer Research Foundation, New York Some authors declared serving as members of independent data monitoring committees or receiving grants or personal fees from several sources.
Source: Cannioto RA et al. Adherence to cancer prevention lifestyle recommendations before, during, and 2 years after treatment for high-risk breast cancer. JAMA Netw Open. 2023;6(5):e2311673 (May 4). Doi: 10.1001/jamanetworkopen.2023.11673
Key clinical point: Adherence to the American Institute for Cancer Research and American Cancer Society’s lifestyle recommendations reduced the risk for disease recurrence and improved mortality in patients with high-risk breast cancer (BC).
Major finding: Patients in the highest vs lowest tertile of lifestyle index scores (LIS) experienced a 37% reduction in recurrence (hazard ratio [HR] 0.63; 95% CI 0.48-0.82) and those in the middle (HR 0.70; P = .03) and highest (HR 0.42; P < .001) vs lowest tertile of LIS had significant reductions in mortality.
Study details: Findings are from the prospective, observational, DELCaP (The Diet, Exercise, Lifestyles, and Cancer Prognosis) study including 1340 chemotherapy-naive women with high-risk stage I to III BC, of which the majority (65.3%) of women had hormone receptor-positive BC.
Disclosures: This study was supported by the US National Cancer Institute and The Breast Cancer Research Foundation, New York Some authors declared serving as members of independent data monitoring committees or receiving grants or personal fees from several sources.
Source: Cannioto RA et al. Adherence to cancer prevention lifestyle recommendations before, during, and 2 years after treatment for high-risk breast cancer. JAMA Netw Open. 2023;6(5):e2311673 (May 4). Doi: 10.1001/jamanetworkopen.2023.11673
Key clinical point: Adherence to the American Institute for Cancer Research and American Cancer Society’s lifestyle recommendations reduced the risk for disease recurrence and improved mortality in patients with high-risk breast cancer (BC).
Major finding: Patients in the highest vs lowest tertile of lifestyle index scores (LIS) experienced a 37% reduction in recurrence (hazard ratio [HR] 0.63; 95% CI 0.48-0.82) and those in the middle (HR 0.70; P = .03) and highest (HR 0.42; P < .001) vs lowest tertile of LIS had significant reductions in mortality.
Study details: Findings are from the prospective, observational, DELCaP (The Diet, Exercise, Lifestyles, and Cancer Prognosis) study including 1340 chemotherapy-naive women with high-risk stage I to III BC, of which the majority (65.3%) of women had hormone receptor-positive BC.
Disclosures: This study was supported by the US National Cancer Institute and The Breast Cancer Research Foundation, New York Some authors declared serving as members of independent data monitoring committees or receiving grants or personal fees from several sources.
Source: Cannioto RA et al. Adherence to cancer prevention lifestyle recommendations before, during, and 2 years after treatment for high-risk breast cancer. JAMA Netw Open. 2023;6(5):e2311673 (May 4). Doi: 10.1001/jamanetworkopen.2023.11673